Latest News •
Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes
Revathi Sekar, Karsten Motzler, Yun Kwon, Aaron Novikoff, Julia Jülg, Bahar Najafi, Surui Wang, Anna-Luisa Warnke, Susanne Seitz, Daniela Hass, Sofiya Gancheva, Sabine Kahl, Bin Yang, Brian Finan, Kathrin Schwarz, Juergen G Okun, Michael Roden, Matthias Blüher, Timo D Müller, [read more…]
Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretion
Willemien van Zwol, Antoine Rimbert, Justina C. Wolters, Marieke Smit, Vincent W. Bloks, Niels J. Kloosterhuis, Nicolette C. A. Huijkman, Mirjam H. Koster, Umesh Tharehalli, Simon M. de Neck, Colin Bournez, Marceline M. Fuh, Jeroen Kuipers, Sujith Rajan, Alain de [read more…]
About Metabolic Syndrom •
Metabolic syndrome (MetS) is a collection of pathological conditions that include abdominal obesity, increased blood pressure, insulin resistance and increased blood glucose and lipids. MetS is a risk factor for type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). Combined, these cardio-metabolic diseases form a heavy burden on our society and health care system. Clearly, increasing our knowledge on the molecular mechanisms contributing to the maintenance of metabolic homeostasis will provide tools to improve prognosis, diagnosis and ultimately treatment of patients with cardio-metabolic diseases.

About Metabolic Syndrom •

Metabolic syndrome (MetS) is a collection of pathological conditions that include abdominal obesity, increased blood pressure, insulin resistance and increased blood glucose and lipids. MetS is a risk factor for type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). Combined, these cardio-metabolic diseases form a heavy burden on our society and health care system. Clearly, increasing our knowledge on the molecular mechanisms contributing to the maintenance of metabolic homeostasis will provide tools to improve prognosis, diagnosis and ultimately treatment of patients with cardio-metabolic diseases.
Mission & Ambition •

It is the ambition of EndoConnect to bring top scientists and industrial partners from different European countries (the Netherlands, Germany, UK, Finland, Spain, Switzerland) together to train PhD students in interdisciplinary research, with the focus on translating key findings from cellular and animal models to patients with cardio-metabolic diseases.
EndoConnect will provide an international training program for PhD students to acquire knowledge and state-of-the-art scientific, technical, and transferable skills to connect molecular and cell biology research with physiology and biomedical research towards translation. This training will significantly increase the career perspectives of PhDs and allow them to become the future leaders in this emerging interdisciplinary field, both in a scientific and societal manner.
Work Packages •
Our Team •
Principal investigators & management

Bart van de Sluis

Heleen van den Heuvel

Pete Cullen

Judith Klumperman

Anja Zeigerer

Jörg Heeren

Jan Albert Kuivenhoven

Albert Pol

Pablo Sáez

Helen Boyd

Kevin Moreau

Elina Ikonen

Noam Zelcer

Alain de Bruin

Marta Bosch

Raymond Schiffelers
PhD students

Shrestha Shaw

Rebeka Butkovic

Camilla Ruffilli

Matteo Tantucci

Klevis Ndoj

Carmen Paredes Yubero

Gyana Lipsa Parida

Joël Tissink

Orsolya Farkas

Ankia Visser

Kim Hurkmans

David McGrath

Alejandra Puentes

Haoran Li
